Search

Your search keyword '"Matsumoto, Shingo"' showing total 1,442 results
Start Over Author "Matsumoto, Shingo"
1,442 results on '"Matsumoto, Shingo"'

53. A Minimum Of 100 Tumor Cells in a Single Biopsy Sample Is Required to Assess Programmed Cell Death Ligand 1 Expression in Predicting Patient Response to Nivolumab Treatment in Nonsquamous Non–Small Cell Lung Carcinoma

Author

Naito, Tomoyuki, Udagawa, Hibiki, Sato, Jun, Horinouchi, Hidehito, Murakami, Shuji, Goto, Yasushi, Kanda, Shintaro, Fujiwara, Yutaka, Yamamoto, Noboru, Zenke, Yoshitaka, Kirita, Keisuke, Matsumoto, Shingo, Yoh, Kiyotaka, Niho, Seiji, Motoi, Noriko, Ohe, Yuichiro, Ishii, Genichiro, and Goto, Koichi

Published
2019
Full Text
View/download PDF

57. Long‐term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study.

Author

Morise, Masahiro, Kato, Terufumi, Matsumoto, Shingo, Inoue, Takako, Sakamoto, Tomohiro, Tokito, Takaaki, Atagi, Shinji, Kozuki, Toshiyuki, Takeoka, Hiroaki, Chikamori, Kenichi, Shinagawa, Naofumi, Tanaka, Hiroshi, Horii, Eisuke, Adrian, Svenja, Bruns, Rolf, Johne, Andreas, Paik, Paul K., and Sakai, Hiroshi

Abstract

Tepotinib is a highly selective MET tyrosine kinase inhibitor (TKI) that has demonstrated robust and durable clinical activity in patients with MET exon 14 (METex14) skipping non–small‐cell lung cancer (NSCLC). In the Phase II VISION study, patients received oral tepotinib 500 mg once daily. The primary endpoint was an objective response by an independent review committee (IRC) according to RECIST v1.1 criteria. The secondary endpoints included duration of response (DOR), progression‐free survival (PFS), overall survival (OS), and safety. Here we report the analysis of the efficacy and safety of tepotinib in all Japanese patients with advanced METex14 skipping NSCLC from VISION (n = 38) with >18 months' follow‐up. The median age of the Japanese patients was 73 years (range 63–88), 39.5% of patients were ≥75 years old, 68.4% were male, 55.3% had a history of smoking, 76.3% had adenocarcinoma, and 10.5% of patients had known brain metastases at baseline. Overall, the objective response rate (ORR) was 60.5% (95% confidence interval (CI): 43.4, 76.0) with a median DOR of 18.5 months (95% CI: 8.3, not estimable). ORR in treatment‐naïve patients (n = 18) was 77.8% (95% CI: 52.4, 93.6), and in patients aged ≥75 years (n = 15), ORR was 73.3% (95% CI: 44.9, 92.2). The most common treatment‐related adverse event (AE) with any grade was blood creatinine increase (65.8%), which resolved following tepotinib discontinuation. Other common treatment‐related AEs were peripheral edema (60.5%), hypoalbuminemia (34.2%), diarrhea (28.9%), and nausea (15.8%). In summary, tepotinib demonstrated robust and durable clinical activity irrespective of age or therapy line, with a manageable safety profile in Japanese patients with METex14 skipping NSCLC enrolled in VISION. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

58. Identification of telomere maintenance gene variations related to lung adenocarcinoma risk by genome‐wide association and whole genome sequencing analyses.

Author

Shiraishi, Kouya, Takahashi, Atsushi, Momozawa, Yukihide, Daigo, Yataro, Kaneko, Syuzo, Kawaguchi, Takahisa, Kunitoh, Hideo, Matsumoto, Shingo, Horinouchi, Hidehito, Goto, Akiteru, Honda, Takayuki, Shimizu, Kimihiro, Torasawa, Masahiro, Takayanagi, Daisuke, Saito, Motonobu, Saito, Akira, Ohe, Yuichiro, Watanabe, Shun‐ichi, Goto, Koichi, and Tsuboi, Masahiro

Published
2024
Full Text
View/download PDF

59. Calcium channel blocker and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction

Author

Matsumoto, Shingo, primary, Kondo, Toru, additional, Yang, Mingming, additional, Campbell, Ross T, additional, Docherty, Kieran F., additional, de Boer, Rudolf A., additional, Desai, Akshay S., additional, Lam, Carolyn S.P., additional, Packer, Milton, additional, Pitt, Bertram, additional, Rouleau, Jean L., additional, Vaduganathan, Muthiah, additional, Zannad, Faiez, additional, Zile, Michael R., additional, Solomon, Scott D., additional, Jhund, Pardeep S., additional, and McMurray, John J.V., additional

Published
2023
Full Text
View/download PDF

61. HER4 and EGFR activate cell signaling in NRG1 fusion-driven cancers: implications for HER2/HER3-specific vs. pan-HER targeting strategies

Author

Udagawa, Hibiki, primary, Nilsson, Monique B., additional, Robichaux, Jacqulyne P., additional, He, Junqin, additional, Poteete, Alissa, additional, Jiang, Hong, additional, Heeke, Simon, additional, Elamin, Yasir Y., additional, Shibata, Yuji, additional, Matsumoto, Shingo, additional, Yoh, Kiyotaka, additional, Okazaki, Shogo, additional, Masuko, Takashi, additional, Odintsov, Ignor, additional, Somwar, Romel, additional, Ladanyi, Marc, additional, Goto, Koichi, additional, and Heymach, John V., additional

Published
2023
Full Text
View/download PDF

65. Prognostic impact and gene expression analysis of peri‐tumoral alveolar macrophage in resected lung adenocarcinoma

Author

Kagawa, Yosuke, primary, Nakai, Tokiko, additional, Taki, Tetsuro, additional, Hashimoto, Hiroko, additional, Tanaka, Yu, additional, Sakai, Tetsuya, additional, Shibata, Yuji, additional, Izumi, Hiroki, additional, Nosaki, Kaname, additional, Udagawa, Hibiki, additional, Zenke, Yoshitaka, additional, Matsumoto, Shingo, additional, Yoh, Kiyotaka, additional, Miyazaki, Saori, additional, Watanabe, Reiko, additional, Kojima, Motohiro, additional, Sakashita, Shingo, additional, Sakamoto, Naoya, additional, Tsuboi, Masahiro, additional, Goto, Koichi, additional, and Ishii, Genichiro, additional

Published
2023
Full Text
View/download PDF

71. Calcium channel blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction.

Author

Matsumoto, Shingo, Kondo, Toru, Yang, Mingming, Campbell, Ross T., Docherty, Kieran F., de Boer, Rudolf A., Desai, Akshay S., Lam, Carolyn S.P., Packer, Milton, Pitt, Bertram, Rouleau, Jean L., Vaduganathan, Muthiah, Zannad, Faiez, Zile, Michael R., Solomon, Scott D., Jhund, Pardeep S., and McMurray, John J.V.

Subjects
*HEART failure patients, *CALCIUM antagonists, *VENTRICULAR ejection fraction, *TREATMENT effectiveness, *HEART failure
Abstract

Aims: Patients with heart failure (HF) and mildly reduced ejection fraction (HFmrEF) and preserved ejection fraction (HFpEF) are often treated with calcium channel blockers (CCBs), although the safety of CCBs in these patients is uncertain. We aimed to investigate the association between CCB use and clinical outcomes in patients with HFmrEF/HFpEF; CCBs were examined overall, as well as by subtype (dihydropyridine and non‐dihydropyridine). Methods and results: We pooled individual patient data from four large HFpEF/HFmrEF trials. The association between CCB use and outcomes was assessed. Among the 16 954 patients included, the mean left ventricular ejection fraction (LVEF) was 56.8%, and 13 402 (79.0%) had HFpEF (LVEF ≥50%). Altogether, 5874 patients (34.6%) received a CCB (87.6% dihydropyridines). Overall, the risks of death and HF hospitalization were not higher in patients treated with a CCB, particularly dihydropyridines. The risk of pump failure death was significantly lower (hazard ratio [HR] 0.76, 95% confidence interval [CI] 0.60–0.96), while the risk of stroke was higher (HR 1.26, 95% CI 1.06–1.50) in patients treated with a CCB compared to those not. These risks remained different in patients treated and not treated with a CCB after adjustment for other prognostic variables. Although the majority of patients were treated with dihydropyridine CCBs, the pattern of outcomes was broadly similar for both dihydropyridine and non‐dihydropyridine CCBs. Conclusion: Although this is an observational analysis of non‐randomized treatment, there was no suggestion that CCBs were associated with worse HF outcomes. Indeed, CCB use was associated with a lower incidence of pump failure death. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

72. Inserting a lithiation potential gap as a factor for degradation control in aluminum-foil anodes by utilizing roll-bonding processes.

Author

Li, Hongyi, Nishimura, Shohei, Nakata, Yuki, Matsumoto, Shingo, Yamaguchi, Takitaro, Hoshikawa, Hiroaki, Kumagai, Toshiaki, and Ichitsubo, Tetsu

Abstract

During cycles, Al-foil anodes for lithium batteries are degraded by the progressive structure fracture of the Al matrix and the surface passivation by the electrolyte decomposition products. In this work, focusing on the structural design to regulate the degradation of the Al-foil anodes, we compare the lithiation potential of four types of Al foils, including high purity 99.99%Al, Al-1%Si, Mn-based A3003 and Mg-based A5052 foils, and prepare clad Al foils by roll-bonding processes to utilize the potential difference between the foils as a control factor. The alloy additions (Si, Mn, and Mg) in the Al foils produce distinct strain effects during lithiation, resulting in variation in the reaction potential. Incorporating different Al foils into a single clad Al foil creates a lithiation potential gap within the anodes, providing an intelligent method for limiting the reaction depth of the Al-foil anodes. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

75. Supplementary Tables S1-S4 from A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid)

Author

Sugimoto, Akira, primary, Matsumoto, Shingo, primary, Udagawa, Hibiki, primary, Itotani, Ryo, primary, Usui, Yuko, primary, Umemura, Shigeki, primary, Nishino, Kazumi, primary, Nakachi, Ichiro, primary, Kuyama, Shoichi, primary, Daga, Haruko, primary, Hara, Satoshi, primary, Miyamoto, Shingo, primary, Kato, Terufumi, primary, Sakakibara-Konishi, Jun, primary, Tabata, Eriko, primary, Nakagawa, Taku, primary, Kawaguchi, Tomoya, primary, Sakai, Tetsuya, primary, Shibata, Yuji, primary, Izumi, Hiroki, primary, Nosaki, Kaname, primary, Zenke, Yoshitaka, primary, Yoh, Kiyotaka, primary, and Goto, Koichi, primary

Published
2023
Full Text
View/download PDF

76. Supplementary Figures S1-S4 from A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid)

Author

Sugimoto, Akira, primary, Matsumoto, Shingo, primary, Udagawa, Hibiki, primary, Itotani, Ryo, primary, Usui, Yuko, primary, Umemura, Shigeki, primary, Nishino, Kazumi, primary, Nakachi, Ichiro, primary, Kuyama, Shoichi, primary, Daga, Haruko, primary, Hara, Satoshi, primary, Miyamoto, Shingo, primary, Kato, Terufumi, primary, Sakakibara-Konishi, Jun, primary, Tabata, Eriko, primary, Nakagawa, Taku, primary, Kawaguchi, Tomoya, primary, Sakai, Tetsuya, primary, Shibata, Yuji, primary, Izumi, Hiroki, primary, Nosaki, Kaname, primary, Zenke, Yoshitaka, primary, Yoh, Kiyotaka, primary, and Goto, Koichi, primary

Published
2023
Full Text
View/download PDF

77. Data from A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid)

Author

Sugimoto, Akira, primary, Matsumoto, Shingo, primary, Udagawa, Hibiki, primary, Itotani, Ryo, primary, Usui, Yuko, primary, Umemura, Shigeki, primary, Nishino, Kazumi, primary, Nakachi, Ichiro, primary, Kuyama, Shoichi, primary, Daga, Haruko, primary, Hara, Satoshi, primary, Miyamoto, Shingo, primary, Kato, Terufumi, primary, Sakakibara-Konishi, Jun, primary, Tabata, Eriko, primary, Nakagawa, Taku, primary, Kawaguchi, Tomoya, primary, Sakai, Tetsuya, primary, Shibata, Yuji, primary, Izumi, Hiroki, primary, Nosaki, Kaname, primary, Zenke, Yoshitaka, primary, Yoh, Kiyotaka, primary, and Goto, Koichi, primary

Published
2023
Full Text
View/download PDF

78. Supplementary Figure from A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid)

Author

Sugimoto, Akira, primary, Matsumoto, Shingo, primary, Udagawa, Hibiki, primary, Itotani, Ryo, primary, Usui, Yuko, primary, Umemura, Shigeki, primary, Nishino, Kazumi, primary, Nakachi, Ichiro, primary, Kuyama, Shoichi, primary, Daga, Haruko, primary, Hara, Satoshi, primary, Miyamoto, Shingo, primary, Kato, Terufumi, primary, Sakakibara-Konishi, Jun, primary, Tabata, Eriko, primary, Nakagawa, Taku, primary, Kawaguchi, Tomoya, primary, Sakai, Tetsuya, primary, Shibata, Yuji, primary, Izumi, Hiroki, primary, Nosaki, Kaname, primary, Zenke, Yoshitaka, primary, Yoh, Kiyotaka, primary, and Goto, Koichi, primary

Published
2023
Full Text
View/download PDF

79. Supplementary Data from A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid)

Author

Sugimoto, Akira, primary, Matsumoto, Shingo, primary, Udagawa, Hibiki, primary, Itotani, Ryo, primary, Usui, Yuko, primary, Umemura, Shigeki, primary, Nishino, Kazumi, primary, Nakachi, Ichiro, primary, Kuyama, Shoichi, primary, Daga, Haruko, primary, Hara, Satoshi, primary, Miyamoto, Shingo, primary, Kato, Terufumi, primary, Sakakibara-Konishi, Jun, primary, Tabata, Eriko, primary, Nakagawa, Taku, primary, Kawaguchi, Tomoya, primary, Sakai, Tetsuya, primary, Shibata, Yuji, primary, Izumi, Hiroki, primary, Nosaki, Kaname, primary, Zenke, Yoshitaka, primary, Yoh, Kiyotaka, primary, and Goto, Koichi, primary

Published
2023
Full Text
View/download PDF

80. Data from Metabolic and Physiologic Imaging Biomarkers of the Tumor Microenvironment Predict Treatment Outcome with Radiation or a Hypoxia-Activated Prodrug in Mice

Author

Matsumoto, Shingo, primary, Kishimoto, Shun, primary, Saito, Keita, primary, Takakusagi, Yoichi, primary, Munasinghe, Jeeva P., primary, Devasahayam, Nallathamby, primary, Hart, Charles P., primary, Gillies, Robert J., primary, Mitchell, James B., primary, and Krishna, Murali C., primary

Published
2023
Full Text
View/download PDF

81. Figure S3 from Metabolic and Physiologic Imaging Biomarkers of the Tumor Microenvironment Predict Treatment Outcome with Radiation or a Hypoxia-Activated Prodrug in Mice

Author

Matsumoto, Shingo, primary, Kishimoto, Shun, primary, Saito, Keita, primary, Takakusagi, Yoichi, primary, Munasinghe, Jeeva P., primary, Devasahayam, Nallathamby, primary, Hart, Charles P., primary, Gillies, Robert J., primary, Mitchell, James B., primary, and Krishna, Murali C., primary

Published
2023
Full Text
View/download PDF

82. Supplemental Tables 1-4 from Podoplanin-Positive Cancer-Associated Fibroblasts in the Tumor Microenvironment Induce Primary Resistance to EGFR-TKIs in Lung Adenocarcinoma with EGFR Mutation

Author

Yoshida, Tatsuya, primary, Ishii, Genichiro, primary, Goto, Koichi, primary, Neri, Shinya, primary, Hashimoto, Hiroko, primary, Yoh, Kiyotaka, primary, Niho, Seiji, primary, Umemura, Shigeki, primary, Matsumoto, Shingo, primary, Ohmatsu, Hironobu, primary, Iida, Shinsuke, primary, Niimi, Akio, primary, Nagai, Kanji, primary, Ohe, Yuichiro, primary, and Ochiai, Atsushi, primary

Published
2023
Full Text
View/download PDF

83. Supplementary Tables from Metabolic Determinants of Sensitivity to Phosphatidylinositol 3-Kinase Pathway Inhibitor in Small-Cell Lung Carcinoma

Author

Makinoshima, Hideki, primary, Umemura, Shigeki, primary, Suzuki, Ayako, primary, Nakanishi, Hiroki, primary, Maruyama, Ami, primary, Udagawa, Hibiki, primary, Mimaki, Sachiyo, primary, Matsumoto, Shingo, primary, Niho, Seiji, primary, Ishii, Genichiro, primary, Tsuboi, Masahiro, primary, Ochiai, Atsushi, primary, Esumi, Hiroyasu, primary, Sasaki, Takehiko, primary, Goto, Koichi, primary, and Tsuchihara, Katsuya, primary

Published
2023
Full Text
View/download PDF

84. Supplementary Methods from Genomic Profiling of Large-Cell Neuroendocrine Carcinoma of the Lung

Author

Miyoshi, Tomohiro, primary, Umemura, Shigeki, primary, Matsumura, Yuki, primary, Mimaki, Sachiyo, primary, Tada, Satoshi, primary, Makinoshima, Hideki, primary, Ishii, Genichiro, primary, Udagawa, Hibiki, primary, Matsumoto, Shingo, primary, Yoh, Kiyotaka, primary, Niho, Seiji, primary, Ohmatsu, Hironobu, primary, Aokage, Keiju, primary, Hishida, Tomoyuki, primary, Yoshida, Junji, primary, Nagai, Kanji, primary, Goto, Koichi, primary, Tsuboi, Masahiro, primary, and Tsuchihara, Katsuya, primary

Published
2023
Full Text
View/download PDF

85. Supplementary Information from Metabolic Determinants of Sensitivity to Phosphatidylinositol 3-Kinase Pathway Inhibitor in Small-Cell Lung Carcinoma

Author

Makinoshima, Hideki, primary, Umemura, Shigeki, primary, Suzuki, Ayako, primary, Nakanishi, Hiroki, primary, Maruyama, Ami, primary, Udagawa, Hibiki, primary, Mimaki, Sachiyo, primary, Matsumoto, Shingo, primary, Niho, Seiji, primary, Ishii, Genichiro, primary, Tsuboi, Masahiro, primary, Ochiai, Atsushi, primary, Esumi, Hiroyasu, primary, Sasaki, Takehiko, primary, Goto, Koichi, primary, and Tsuchihara, Katsuya, primary

Published
2023
Full Text
View/download PDF

86. Supplementary Fig. S8 from Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK-Rearranged/TP53-Mutant NSCLC via Noxa Expression

Author

Tanimoto, Azusa, primary, Matsumoto, Shingo, primary, Takeuchi, Shinji, primary, Arai, Sachiko, primary, Fukuda, Koji, primary, Nishiyama, Akihiro, primary, Yoh, Kiyotaka, primary, Ikeda, Takaya, primary, Furuya, Naoki, primary, Nishino, Kazumi, primary, Ohe, Yuichiro, primary, Goto, Koichi, primary, and Yano, Seiji, primary

Published
2023
Full Text
View/download PDF

87. Table S1 from Metabolic and Physiologic Imaging Biomarkers of the Tumor Microenvironment Predict Treatment Outcome with Radiation or a Hypoxia-Activated Prodrug in Mice

Author

Matsumoto, Shingo, primary, Kishimoto, Shun, primary, Saito, Keita, primary, Takakusagi, Yoichi, primary, Munasinghe, Jeeva P., primary, Devasahayam, Nallathamby, primary, Hart, Charles P., primary, Gillies, Robert J., primary, Mitchell, James B., primary, and Krishna, Murali C., primary

Published
2023
Full Text
View/download PDF

88. Supplementary Tables from Amplification of EGFR Wild-Type Alleles in Non–Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors

Author

Nukaga, Shigenari, primary, Yasuda, Hiroyuki, primary, Tsuchihara, Katsuya, primary, Hamamoto, Junko, primary, Masuzawa, Keita, primary, Kawada, Ichiro, primary, Naoki, Katsuhiko, primary, Matsumoto, Shingo, primary, Mimaki, Sachiyo, primary, Ikemura, Shinnosuke, primary, Goto, Koichi, primary, Betsuyaku, Tomoko, primary, and Soejima, Kenzo, primary

Published
2023
Full Text
View/download PDF

89. Supplementary Figures from Amplification of EGFR Wild-Type Alleles in Non–Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors

Author

Nukaga, Shigenari, primary, Yasuda, Hiroyuki, primary, Tsuchihara, Katsuya, primary, Hamamoto, Junko, primary, Masuzawa, Keita, primary, Kawada, Ichiro, primary, Naoki, Katsuhiko, primary, Matsumoto, Shingo, primary, Mimaki, Sachiyo, primary, Ikemura, Shinnosuke, primary, Goto, Koichi, primary, Betsuyaku, Tomoko, primary, and Soejima, Kenzo, primary

Published
2023
Full Text
View/download PDF

90. Supplemental Figure legends from Podoplanin-Positive Cancer-Associated Fibroblasts in the Tumor Microenvironment Induce Primary Resistance to EGFR-TKIs in Lung Adenocarcinoma with EGFR Mutation

Author

Yoshida, Tatsuya, primary, Ishii, Genichiro, primary, Goto, Koichi, primary, Neri, Shinya, primary, Hashimoto, Hiroko, primary, Yoh, Kiyotaka, primary, Niho, Seiji, primary, Umemura, Shigeki, primary, Matsumoto, Shingo, primary, Ohmatsu, Hironobu, primary, Iida, Shinsuke, primary, Niimi, Akio, primary, Nagai, Kanji, primary, Ohe, Yuichiro, primary, and Ochiai, Atsushi, primary

Published
2023
Full Text
View/download PDF

91. Data from Metabolic Determinants of Sensitivity to Phosphatidylinositol 3-Kinase Pathway Inhibitor in Small-Cell Lung Carcinoma

Author

Makinoshima, Hideki, primary, Umemura, Shigeki, primary, Suzuki, Ayako, primary, Nakanishi, Hiroki, primary, Maruyama, Ami, primary, Udagawa, Hibiki, primary, Mimaki, Sachiyo, primary, Matsumoto, Shingo, primary, Niho, Seiji, primary, Ishii, Genichiro, primary, Tsuboi, Masahiro, primary, Ochiai, Atsushi, primary, Esumi, Hiroyasu, primary, Sasaki, Takehiko, primary, Goto, Koichi, primary, and Tsuchihara, Katsuya, primary

Published
2023
Full Text
View/download PDF

92. Supplemental Figures 1-6 from Podoplanin-Positive Cancer-Associated Fibroblasts in the Tumor Microenvironment Induce Primary Resistance to EGFR-TKIs in Lung Adenocarcinoma with EGFR Mutation

Author

Yoshida, Tatsuya, primary, Ishii, Genichiro, primary, Goto, Koichi, primary, Neri, Shinya, primary, Hashimoto, Hiroko, primary, Yoh, Kiyotaka, primary, Niho, Seiji, primary, Umemura, Shigeki, primary, Matsumoto, Shingo, primary, Ohmatsu, Hironobu, primary, Iida, Shinsuke, primary, Niimi, Akio, primary, Nagai, Kanji, primary, Ohe, Yuichiro, primary, and Ochiai, Atsushi, primary

Published
2023
Full Text
View/download PDF

93. Supplementary legends from Metabolic Determinants of Sensitivity to Phosphatidylinositol 3-Kinase Pathway Inhibitor in Small-Cell Lung Carcinoma

Author

Makinoshima, Hideki, primary, Umemura, Shigeki, primary, Suzuki, Ayako, primary, Nakanishi, Hiroki, primary, Maruyama, Ami, primary, Udagawa, Hibiki, primary, Mimaki, Sachiyo, primary, Matsumoto, Shingo, primary, Niho, Seiji, primary, Ishii, Genichiro, primary, Tsuboi, Masahiro, primary, Ochiai, Atsushi, primary, Esumi, Hiroyasu, primary, Sasaki, Takehiko, primary, Goto, Koichi, primary, and Tsuchihara, Katsuya, primary

Published
2023
Full Text
View/download PDF

94. supplemental legend from Genomic Profiling of Large-Cell Neuroendocrine Carcinoma of the Lung

Author

Miyoshi, Tomohiro, primary, Umemura, Shigeki, primary, Matsumura, Yuki, primary, Mimaki, Sachiyo, primary, Tada, Satoshi, primary, Makinoshima, Hideki, primary, Ishii, Genichiro, primary, Udagawa, Hibiki, primary, Matsumoto, Shingo, primary, Yoh, Kiyotaka, primary, Niho, Seiji, primary, Ohmatsu, Hironobu, primary, Aokage, Keiju, primary, Hishida, Tomoyuki, primary, Yoshida, Junji, primary, Nagai, Kanji, primary, Goto, Koichi, primary, Tsuboi, Masahiro, primary, and Tsuchihara, Katsuya, primary

Published
2023
Full Text
View/download PDF

95. Supplementary Tables from Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK-Rearranged/TP53-Mutant NSCLC via Noxa Expression

Author

Tanimoto, Azusa, primary, Matsumoto, Shingo, primary, Takeuchi, Shinji, primary, Arai, Sachiko, primary, Fukuda, Koji, primary, Nishiyama, Akihiro, primary, Yoh, Kiyotaka, primary, Ikeda, Takaya, primary, Furuya, Naoki, primary, Nishino, Kazumi, primary, Ohe, Yuichiro, primary, Goto, Koichi, primary, and Yano, Seiji, primary

Published
2023
Full Text
View/download PDF

96. Supplementary Figures from Genomic Profiling of Large-Cell Neuroendocrine Carcinoma of the Lung

Author

Miyoshi, Tomohiro, primary, Umemura, Shigeki, primary, Matsumura, Yuki, primary, Mimaki, Sachiyo, primary, Tada, Satoshi, primary, Makinoshima, Hideki, primary, Ishii, Genichiro, primary, Udagawa, Hibiki, primary, Matsumoto, Shingo, primary, Yoh, Kiyotaka, primary, Niho, Seiji, primary, Ohmatsu, Hironobu, primary, Aokage, Keiju, primary, Hishida, Tomoyuki, primary, Yoshida, Junji, primary, Nagai, Kanji, primary, Goto, Koichi, primary, Tsuboi, Masahiro, primary, and Tsuchihara, Katsuya, primary

Published
2023
Full Text
View/download PDF

97. Supplementary figures from Metabolic Determinants of Sensitivity to Phosphatidylinositol 3-Kinase Pathway Inhibitor in Small-Cell Lung Carcinoma

Author

Makinoshima, Hideki, primary, Umemura, Shigeki, primary, Suzuki, Ayako, primary, Nakanishi, Hiroki, primary, Maruyama, Ami, primary, Udagawa, Hibiki, primary, Mimaki, Sachiyo, primary, Matsumoto, Shingo, primary, Niho, Seiji, primary, Ishii, Genichiro, primary, Tsuboi, Masahiro, primary, Ochiai, Atsushi, primary, Esumi, Hiroyasu, primary, Sasaki, Takehiko, primary, Goto, Koichi, primary, and Tsuchihara, Katsuya, primary

Published
2023
Full Text
View/download PDF

98. Supplementary Tables from Genomic Profiling of Large-Cell Neuroendocrine Carcinoma of the Lung

Author

Miyoshi, Tomohiro, primary, Umemura, Shigeki, primary, Matsumura, Yuki, primary, Mimaki, Sachiyo, primary, Tada, Satoshi, primary, Makinoshima, Hideki, primary, Ishii, Genichiro, primary, Udagawa, Hibiki, primary, Matsumoto, Shingo, primary, Yoh, Kiyotaka, primary, Niho, Seiji, primary, Ohmatsu, Hironobu, primary, Aokage, Keiju, primary, Hishida, Tomoyuki, primary, Yoshida, Junji, primary, Nagai, Kanji, primary, Goto, Koichi, primary, Tsuboi, Masahiro, primary, and Tsuchihara, Katsuya, primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results